文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19短期恶化的生物标志物:前瞻性多中心COVIDeF队列的多参数分析

Biomarkers of COVID-19 short-term worsening: a multiparameter analysis within the prospective multicenter COVIDeF cohort.
PubMed 文献 · Eur J Emerg Med · 2024-09-12
一句话结论在COVID-19住院患者中,CRP、降钙素原和MR-proADM与7天内短期恶化独立相关,其预测能力超过除糖尿病和癌症外的临床变量。

本研究为前瞻性多中心(巴黎20家医院)队列,连续纳入2020年法国COVID-19第一波疫情期间的住院患者,入院时系统采集生物样本并检测多种生物标志物,排除采样前已入住ICU、机械通气(含无创通气)、急性呼吸窘迫或院内死亡者。主要终点为7天内出现严重标准(短期恶化,STW)。511例患者中60例(11.7%)发生STW,中位发生时间3天。多因素分析显示CRP(每增加10单位aOR 1.10,95%CI 1.06-1.15)、降钙素原(aOR 0.42,95%CI 0.22-0.81)和MR-proADM(aOR 2.85,95%CI 1.74-4.69)与恶化独立相关,AUROC分别为0.73、0.69和0.75。

要点

  • 511例COVID-19住院患者中60例(11.7%)在7天内发生短期恶化,中位发生时间3天。
  • CRP每增加10单位与恶化独立相关(aOR 1.10,95%CI 1.06-1.15),AUROC 0.73(0.66-0.79)。
  • MR-proADM与恶化独立相关(aOR 2.85,95%CI 1.74-4.69),AUROC 0.75(0.69-0.81)。
  • 降钙素原与恶化独立相关(aOR 0.42,95%CI 0.22-0.81),AUROC 0.69(0.64-0.88)。
  • 上述生物标志物的预测能力超过临床变量,但糖尿病和癌症合并症除外。

适用人群与场景

  • 2020年法国COVID-19第一波疫情期间,巴黎20家医院连续纳入的COVID-19住院患者。
  • 排除采样前已入住ICU、机械通气(含无创通气)、急性呼吸窘迫或院内死亡的患者。

诊断标准与关键阈值

  • 短期恶化(STW)定义为7天内出现严重标准。

研究设计与关键结果

  • 研究设计:前瞻性、多中心(巴黎20家医院)队列研究,连续纳入COVID-19患者,入院时系统生物样本库采集。
  • 样本量:511例患者分析,其中60例(11.7%)发生STW,中位发生时间3天。
  • 单因素分析:入院时嗜酸性粒细胞、淋巴细胞、血小板、丙氨酸氨基转移酶较低,以及中性粒细胞、肌酐、尿素、CRP、TnT-hs、suPAR、NT-proBNP、钙卫蛋白、降钙素原、MR-proADM、前内皮素较高可预测恶化。
  • 多因素分析:CRP每增加10单位aOR 1.10(95%CI 1.06-1.15),AUROC 0.73(0.66-0.79);降钙素原aOR 0.42(95%CI 0.22-0.81),AUROC 0.69(0.64-0.88);MR-proADM aOR 2.85(95%CI 1.74-4.69),AUROC 0.75(0.69-0.81)。
  • 这些生物标志物的预测能力超过临床变量,但糖尿病和癌症合并症除外。

证据类型、等级与局限

  • 证据类型:前瞻性多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于COVID-19住院患者,入院时检测CRP、降钙素原和MR-proADM可能有助于识别7天内短期恶化风险较高的患者。
  • 作者认为CRP、降钙素原和MR-proADM与短期恶化风险独立相关,其预测能力超过除糖尿病和癌症外的临床变量。

指南或共识出处

  • ClinicalTrials.gov NCT04352348

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: During a pandemic like COVID-19, hospital resources are constrained and accurate severity triage of the patients is required.

OBJECTIVE: The objective of this study is to estimate the predictive performances of candidate biomarkers for short-term worsening (STW) of COVID-19.

DESIGN: Prospective, multicenter (20 hospitals in Paris) cohort study of consecutive COVID-19 patients with systematic biobanking at admission, during the first waves of COVID-19 in France in 2020 (COVIDeF cohort).

SETTING AND PARTICIPANTS: Consecutive COVID-19 patients were screened for inclusion. They were excluded in presence of severity criteria defined by either an ICU admission, mechanical ventilation (including noninvasive ventilation), acute respiratory distress, or in-hospital death before sampling. Routine blood tests measured during usual care and centralized systematic measurement of creatine kinase, C-reactive protein (CRP), procalcitonin, soluble urokinase plasminogen activator receptor (suPAR), high-sensitive troponin T (TnT-hs), N terminal pro-B natriuretic peptide (NT-proBNP), calprotectin, platelet factor 4, mid-regional pro-adrenomedullin (MR-proADM), and proendothelin were performed.

OUTCOME MEASURES AND ANALYSES: The primary outcome was STW, defined by a severity criteria within 7 days. A backward stepwise logistic regression model and a 'best subset' approach were used to identify independent association, and the area under the receiving operator characteristics (AUROC) was computed.

RESULTS: Five hundred and eleven patients were analyzed, of whom 60 (11.7%) experienced STW. Median time to occurrence of a severity criteria was 3 days. At admission, lower values of eosinophils, lymphocytes, platelets, alanine aminotransferase, and higher values of neutrophils, creatinine, urea, CRP, TnT-hs, suPAR, NT-proBNP, calprotectin, procalcitonin, MR-proADM, and proendothelin were predictive of worsening. Stepwise logistic regression identified three biomarkers significantly associated with worsening: CRP [adjusted odds ratio (aOR): 1.10, 95% confidence interval (95% CI): 1.06-1.15 for a 10-unit increase, AUROC: 0.73 (0.66-0.79)], procalcitonin [aOR: 0.42, 95% CI: 0.22-0.81, AUROC: 0.69 (0.64-0.88)], and MR-proADM [aOR: 2.85, 95% CI: 1.74-4.69, AUROC: 0.75 (0.69-0.81)]. These biomarkers outperformed clinical variables except diabetes and cancer comorbidities.

CONCLUSION: In this multicenter prospective study that assessed a large panel of biomarkers for COVID-19 patients, CRP, procalcitonin, and MR-proADM were independently associated with the risk of STW.

TRIAL REGISTRATION: ClinicalTrials.gov NCT04352348.

来源:Eur J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Cancella de Abreu M, Ropers J, Oueidat N, et al. Biomarkers of COVID-19 short-term worsening: a multiparameter analysis within the prospective multicenter COVIDeF cohort. Eur J Emerg Med. 2024. PMID: 39480645. doi:10.1097/MEJ.0000000000001175

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。